nVerses Capital’s Allogene Therapeutics ALLO Stock Holding History

nVerses Capital’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,100	Closed	-$8.68K	–	34
2024 Q3	$8.68K	Buy	+3,100	New	+$8.26K	﹤0.01%	904

Other funds holding ALLO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

nVerses Capital's ALLO Position: Q4 2024 in Review

nVerses Capital sold out of Allogene Therapeutics (ALLO) in Q4 2024, closing a stake of 3,100 shares — an estimated $8.68K sold.

nVerses Capital first reported a position in ALLO in Q3 2024 and held it in 1 quarter. The position peaked at $8.68K in Q3 2024. 174 funds tracked by Wall St. Rank hold ALLO as of Q4 2024.

nVerses Capital reported no remaining Allogene Therapeutics position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 3,100 Allogene Therapeutics shares in Q4 2024, an estimated $8.68K.
nVerses Capital first reported a position in Allogene Therapeutics in Q3 2024 and held it in 1 quarter.
nVerses Capital's Allogene Therapeutics position peaked at $8.68K in Q3 2024.
174 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.